Literature DB >> 8317409

Elevation of phospholipase A2 protein in sera of patients with Crohn's disease and ulcerative colitis.

T Minami1, H Tojo, Y Shinomura, T Komatsubara, Y Matsuzawa, M Okamoto.   

Abstract

The protein mass of group II phospholipase A2 (PLA2) levels were immunochemically measured in sera of 43 patients with Crohn's disease (CD), 43 patients with ulcerative colitis (UC), and 35 healthy volunteers, and compared with PLA2 enzymatic activity. Serum immunoreactive group II PLA2 (IR-PLA2 II) levels of active CD patients were significantly higher than those of the controls and inactive CD patients. Serum IR-PLA2 II levels were also significantly greater in patients with severe UC and moderate UC than in the controls and patients with mild UC. Serum IR-PLA2 II levels were found to be closely correlated with serum PLA2 activity in patients with CD and UC. Serum IR-PLA2 II levels and PLA2 activity decreased by antiinflammatory treatment in six patients with CD and two with UC. These results suggest that serum IR-PLA2 II levels can be a useful parameter in the evaluation of disease activity of CD and UC, and that elevated PLA2 enzymatic activity in sera of patients with CD and UC is attributable to increased protein concentration of group II PLA2, in agreement with our previous results.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8317409

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  8 in total

1.  Phospholipase A2 secretion during intestinal graft ischemia.

Authors:  R E Sonnino; L Pigatt; A Schrama; S Burchett; R Franson
Journal:  Dig Dis Sci       Date:  1997-05       Impact factor: 3.199

2.  Interleukin-6 changes tight junction permeability and intracellular phospholipid content in a human enterocyte cell culture model.

Authors:  Y Tazuke; R A Drongowski; D H Teitelbaum; A G Coran
Journal:  Pediatr Surg Int       Date:  2003-05-06       Impact factor: 1.827

3.  TRPM8 activation attenuates inflammatory responses in mouse models of colitis.

Authors:  Rithwik Ramachandran; Eric Hyun; Liena Zhao; Tamia K Lapointe; Kevin Chapman; Christina L Hirota; Subrata Ghosh; David D McKemy; Nathalie Vergnolle; Paul L Beck; Christophe Altier; Morley D Hollenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-17       Impact factor: 11.205

4.  Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis.

Authors:  T Minami; H Tojo; Y Shinomura; Y Matsuzawa; M Okamoto
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

5.  Sequence specific inhibition of human type II phospholipase A2 enzyme activity by phosphorothioate oligonucleotides.

Authors:  C F Bennett; M Y Chiang; L Wilson-Lingardo; J R Wyatt
Journal:  Nucleic Acids Res       Date:  1994-08-11       Impact factor: 16.971

6.  Bactericidal properties of murine intestinal phospholipase A2.

Authors:  S S Harwig; L Tan; X D Qu; Y Cho; P B Eisenhauer; R I Lehrer
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

7.  Molecular Modeling-Guided Design of Phospholipid-Based Prodrugs.

Authors:  Milica Markovic; Shimon Ben-Shabat; Shahar Keinan; Aaron Aponick; Ellen M Zimmermann; Arik Dahan
Journal:  Int J Mol Sci       Date:  2019-05-05       Impact factor: 5.923

8.  Group II phospholipase A(2) in human gingiva with periodontal disease.

Authors:  H Shinohara; T Komatsubara; H Tojo; M Okamoto; S Nishikawa; T Nagata; H Ishida
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.